期刊
ONCOTARGET
卷 7, 期 8, 页码 8993-9006出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7113
关键词
nanoformulation; nanomedicine; niclosamide; ovarian cancer; cancer metabolism
资金
- National Health Research Institution of Taiwan
- National Science Council of Taiwan
- Taipei Medical University
- Tri-Service General Hospital
- Tri-Service General Hospital-National Taiwan University of Science and Technology Joint Research Program [TSGH-NTUST-104-04]
- [NHRI-EX104-10406BI]
- [TMU-NDMC-104-05]
- [104TMU-SHH-07]
- [TMUTOP103005-1]
- [TMU103-AE1-B06 TSGH-C104-006-006-008-S01,-S02,-S03]
- [TSGH-C104-012]
- [NSC 102-2314-B-016-043 (NLAC102)]
Ovarian cancer treatment remains a challenge and targeting cancer stem cells presents a promising strategy. Niclosamide is an old antihelminthic drug that uncouples mitochondria of intestinal parasites. Although recent studies demonstrated that niclosamide could be a potential anticancer agent, its poor water solubility needs to be overcome before further preclinical and clinical investigations can be conducted. Therefore, we evaluated a novel nanosuspension of niclosamide (nano-NI) for its effect against ovarian cancer. Nano-NI effectively inhibited the growth of ovarian cancer cells in which it induced a metabolic shift to glycolysis at a concentration of less than 3 mu M in vitro and suppressed tumor growth without obvious toxicity at an oral dose of 100 mg/kg in vivo. In a pharmacokinetic study after oral administration, nano-NI showed rapid absorption (reaching the maximum plasma concentration within 5 min) and improved the bioavailability (the estimated bioavailability for oral nano-NI was 25%). In conclusion, nano-NI has the potential to be a new treatment modality for ovarian cancer and, therefore, further clinical trials are warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据